Read our latest updates & insights

On 4 February 2026, Mexican-headquartered Saya Biologics announced that it has entered a strategic collaboration agreement with Kashiv BioSciences for commercialisation of an undisclosed supportive biosimilar oncology therapy in Mexico and the Central America and Caribbean ...

On 4 February 2026, R-Pharm announced it has obtained Russian marketing authorisation for the anti-cancer drug Arcetux™, biosimilar to Eli Lilly/Merck KgGa’s Erbitux® (cetuximab).  This is the first biosimilar cetuximab to be approved in Russia.

Arcetux™ has been app...

On 3 February 2026, Bio-Thera Solutions and Saudi-based Avalon Pharma announced that they have entered commercialisation and licence agreements for Bio-Thera’s BAT3306, biosimilar to MSD’s Keytruda® (pembrolizumab), in Saudi Arabia and MENA.

Under the agreement, Aval...

On 3 February 2026, Amgen announced its financial results for Q4/2025 and full year 2025, including providing the following update on its biosimilar pipeline:

Nivolumab: Amgen has completed enrolment in a comparative clinical study comparing ABP 206 (nivolumab) wit...

On 2 February 2026, Alvotech announced that it has entered into supply and commercialisation agreements with Sandoz for multiple unidentified biosimilars for Australia, New Zealand and Canada.

In Australia and New Zealand, the agreement covers three biosimilars acros...

On 2 February 2026, R-Pharm announced that the Russian Ministry of Health has approved Persinthia™, biosimilar to Genentech/Roche’s Perjeta® (pertuzumab), for the treatment of HER2-positive breast cancer.  The approval follows R-Pharm’s announcement in December 2025 at the ...